<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Potassium chloride: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Potassium chloride: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Potassium chloride: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9795" href="/d/html/9795.html" rel="external">see "Potassium chloride: Drug information"</a> and <a class="drug drug_patient" data-topicid="10982" href="/d/html/10982.html" rel="external">see "Potassium chloride: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F211820"><span class="drugH1">Brand Names: US</span>
<ul>
<li>K-Tab;</li>
<li>Klor-Con;</li>
<li>Klor-Con 10;</li>
<li>Klor-Con M10;</li>
<li>Klor-Con M15;</li>
<li>Klor-Con M20;</li>
<li>Klor-Con Sprinkle [DSC];</li>
<li>Pokonza</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867986"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-K;</li>
<li>Micro-K</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1032206"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Electrolyte Supplement, Oral</span>;</li>
<li>
<span class="list-set-name">Electrolyte Supplement, Parenteral</span></li></ul></div>
<div class="block don drugH1Div" id="F53462552"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Safety: Do NOT administer undiluted or by IV push; may cause fatal cardiac arrest.</b> To prevent adverse effects, adhere to standard dilution(s) and rate(s) of administration while closely monitoring serum potassium levels; cardiac monitoring may be required depending on clinical status and infusion rate.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Oral solutions are available in 2 concentrations: 20 mEq per 15 mL (1.33 mEq/mL) and 40 mEq per 15 mL (2.67 mEq/mL); use extra caution; verify product formulation for dosage calculation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Maintenance potassium IV doses should be incorporated into the patient's maintenance IV fluids; intermittent IV potassium administration should be reserved for severe depletion situations; continuous ECG monitoring should be used for intermittent IV doses &gt;0.5 mEq/kg/<b>hour </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corkins.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corkins.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7b4f01cb-78b4-4e2e-9ec2-19398d5bab52">Hypokalemia, treatment; mild to moderate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypokalemia, treatment; mild to moderate:</b> Neonates: Oral: Initial: 1 to 2 mEq/kg/day in divided doses; titrate to desired clinical response; usual range: 1 to 5 mEq/kg/day; not to exceed 1 to 2 mEq/kg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corkins.1','lexi-content-ref-28378030','lexi-content-ref-Greenbaum.1','lexi-content-ref-21297518','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corkins.1','lexi-content-ref-28378030','lexi-content-ref-Greenbaum.1','lexi-content-ref-21297518','lexi-content-ref-manu.1'])">Ref</a></span>); serum concentrations should be evaluated at least 2 hours after the dose; may repeat dose as needed based on lab values (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corkins.1','lexi-content-ref-21297518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corkins.1','lexi-content-ref-21297518'])">Ref</a></span>); if deficits are severe or ongoing losses are great, IV potassium should be considered as preferred route of administration.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1988e139-ea95-41b9-be4b-84cb139db89b">Hypokalemia, treatment; severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypokalemia, treatment; severe:</b> Neonates: Intermittent IV infusion: 0.5 to 1 mEq/kg/dose; <b>Note: Do NOT administer undiluted or by IV push</b> (see "Administration: Pediatric" for more details on rate). Continuous ECG monitoring is recommended during infusion; see institutional policy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corkins.1','lexi-content-ref-28378030','lexi-content-ref-Greenbaum.1','lexi-content-ref-Lynch.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corkins.1','lexi-content-ref-28378030','lexi-content-ref-Greenbaum.1','lexi-content-ref-Lynch.1'])">Ref</a></span>); serum concentrations should be evaluated 1 to 2 hours after completion of infusion; may repeat as needed based on lab values (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corkins.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corkins.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="97b7bc9f-03a7-4e44-a28d-d32736384506">Parenteral nutrition, maintenance potassium requirement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition, maintenance potassium requirement:</b> Preterm and Term Neonates: IV: 2 to 4 mEq/kg/day of potassium as an additive to parenteral nutrition solution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ASPEN.2019','lexi-content-ref-Corkins.1','lexi-content-ref-15568296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ASPEN.2019','lexi-content-ref-Corkins.1','lexi-content-ref-15568296'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F211833"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: Do NOT administer undiluted or by IV push; may cause fatal cardiac arrest.</b> To prevent adverse effects, adhere to standard dilution(s) and rate(s) of administration while closely monitoring serum potassium levels; cardiac monitoring may be required depending on clinical status and infusion rate.</p>
<p style="text-indent:0em;margin-top:2em;">Maintenance potassium IV doses should be incorporated into the patient's maintenance IV fluids; intermittent IV potassium administration should be reserved for severe depletion situations; continuous ECG monitoring should be used for intermittent IV doses &gt;0.5 mEq/kg/<b>hour</b> (ASPEN [Corkins 2015]). Oral solutions are available in two concentrations: 20 mEq per 15 mL (1.33 mEq/mL) and 40 mEq per 15 mL (2.67 mEq/mL); use extra caution; verify product formulation for dosage calculation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypokalemia, treatment; mild to moderate:</b> Infants, Children, and Adolescents: Oral: Initial: 1 to 2 mEq/kg/day in divided doses; titrate to desired clinical response; usual range: 1 to 5 mEq/kg/day; not to exceed 1 to 2 mEq/kg as a single dose up to 40 mEq/dose (ASPEN [Corkins 2015]; Greenbaum 2020; Lynch 2017; Moffett 2011; manufacturer's labeling); serum concentrations should be evaluated at least 2 hours after the dose; may repeat dose as needed based on lab values (ASPEN [Corkins 2015]; Moffett 2011); if deficits are severe or ongoing losses are great, IV potassium should be considered as preferred route of administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypokalemia, treatment; severe:</b> Infants, Children, and Adolescents: Intermittent IV infusion: 0.5 to 1 mEq/kg/dose; maximum dose: 40 mEq/dose. <b>Note: Do NOT administer undiluted or by IV push</b> (see "Administration: Pediatric" for more details on rate). Continuous ECG monitoring is recommended during infusion; see institutional policy (AAP [Shenoi 2020]; ASPEN [Corkins 2015]; Greenbaum 2020; Lynch 2017); serum concentrations should be evaluated 1 to 2 hours after completion of infusion; may repeat as needed based on lab values (ASPEN [Corkins 2015]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition, maintenance potassium requirement</b> (ASPEN 2020; ASPEN [Corkins 2015]; ASPEN [Mirtallo 2004]):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children weighing ≤50 kg: IV: 2 to 4 mEq/kg/day of potassium as an additive to parenteral nutrition solution.</p>
<p style="text-indent:-2em;margin-left:4em;">Children weighing &gt;50 kg and Adolescents: IV: 1 to 2 mEq/kg/day of potassium as an additive to parenteral nutrition solution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51154205"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: There are no specific dosage adjustments provided in the manufacturer's labeling. In adult patients with renal impairment, reducing the initial dose by at least 50% has been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929'])">Ref</a></span>). Contraindicated in patients with renal failure.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Initiate therapy at the low end of the dosing range, particularly if on other medications known to increase potassium levels; monitor potassium concentration frequently (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51154206"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Use with caution in patients with cirrhosis and start at the low end of dosage range; monitor potassium concentrations frequently (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
<div class="block doa drugH1Div" id="F211823"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9795" href="/d/html/9795.html" rel="external">see "Potassium chloride: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Do <b>NOT</b> administer undiluted or by IV push; may cause fatal cardiac arrest. To prevent adverse effects, adhere to standard dilution(s) and rate(s) of administration while closely monitoring serum potassium levels; cardiac monitoring may be required depending on clinical status and infusion rate (eg, &gt;10 mEq/hour [consider all IV potassium sources]); refer to institutional protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> All doses are expressed as mEq of potassium (1 mEq = 1 mmol potassium).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cdbede25-d23b-4406-9e0e-9fad9e330bfd">Diabetic ketoacidosis or hyperosmolar hyperglycemic state, potassium management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetic ketoacidosis or hyperosmolar hyperglycemic state, potassium management (off-label use): Note:</b> Regardless of initial measured serum potassium, almost all patients with diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) have a total-body potassium deficit. Guide therapy based on patient condition (eg, kidney function, urine output, serum potassium levels) and correct fluid deficits if present. An example of a dosing regimen is as follows; refer to institutional protocols (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19564476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19564476'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Serum potassium &lt;3.3 mEq/L:</i> Note:</b> If serum potassium is &lt;3.3 mEq/L on initial presentation, delay insulin until serum potassium reaches ≥3.3 mEq/L.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initial: 20 to 40 mEq<b>/hour</b>, then supplement as needed and monitor potassium levels frequently (eg, every 1 to 2 hours) until serum potassium ≥3.3 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.1','lexi-content-ref-19564476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.1','lexi-content-ref-19564476'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Serum potassium 3.3 to 5.2 mEq/L:</i> IV:</b> Add 20 to 30 mEq to each liter of IV fluid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19564476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19564476'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Dosage adjustment:</i></b> Adjust dosage to maintain serum potassium levels within target range (eg, 4 to 5 mEq/L) until DKA/HHS resolves (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19564476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19564476'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="04b25be2-c11a-453b-bd96-7677d7805c9b">Hypokalemia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypokalemia, treatment: Note:</b> Dosing requires individualization based on serum potassium levels and clinical factors (eg, underlying cause, presence of symptoms, concomitant medications, ongoing potassium losses). Use caution in patients with redistributive hypokalemia (eg, hypokalemic periodic paralysis, theophylline poisoning), as small amounts of administered potassium may result in rebound hyperkalemia and associated cardiotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gutmann.1','lexi-content-ref-Perry.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gutmann.1','lexi-content-ref-Perry.1'])">Ref</a></span>). Concurrent hypomagnesemia requires correction to facilitate potassium repletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929'])">Ref</a></span>). General guidance is provided below; refer to institutional protocols. After repletion, evaluate need for continued potassium replacement to prevent further episodes of hypokalemia.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Mild to moderate (serum potassium 3 to 3.4 mEq/L): </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 10 to 20 mEq 2 to 4 times daily; base subsequent dosing on serum potassium monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10979053','lexi-content-ref-16085929','lexi-content-ref-Mount.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10979053','lexi-content-ref-16085929','lexi-content-ref-Mount.1'])">Ref</a></span>); maximum single dose: 40 mEq (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV: Note:</b> Generally used when patient is unable to tolerate oral therapy. Central-line infusion and continuous ECG monitoring highly recommended for infusions &gt;10 mEq/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: <b>IV:</b> 20 to 60 mEq once based on serum potassium concentration and clinical factors; maximum infusion rate 10 to 20 mEq/<b>hour</b>; base subsequent dosing on serum potassium monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929','lexi-content-ref-19969151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929','lexi-content-ref-19969151'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Severe (serum potassium &lt;3 mEq/L) or symptomatic:</i></b>
<b> Note: </b>Frequent serum potassium monitoring (eg, every 2 to 4 hours) is recommended to determine subsequent dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929','lexi-content-ref-Mount.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929','lexi-content-ref-Mount.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral </b>(monotherapy or adjunctive with IV): Initial: 40 mEq 3 to 4 times daily or 20 mEq every 2 to 3 hours with adjustment based on frequent serum potassium monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929','lexi-content-ref-Mount.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929','lexi-content-ref-Mount.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b>
<b>Note:</b> Dosing/infusion rate recommendations vary; central-line infusion and continuous ECG monitoring highly recommended for infusions &gt;10 mEq/hour.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Serum potassium 2.5 to 3 mEq/L:</i></b> Initial: <b>IV: </b>10 to 20 mEq/<b>hour</b>; adjust based on frequent serum potassium monitoring; maximum infusion rate: 20 mEq/hour with continuous ECG monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23616673','lexi-content-ref-15977686','lexi-content-ref-MacLaren.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23616673','lexi-content-ref-15977686','lexi-content-ref-MacLaren.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>
<i>Serum potassium &lt;2.5 mEq/L or life-threatening hypokalemia (not for emergency treatment of cardiac arrest):</i></b> Initial: <b>IV: </b>10 to 40 mEq/<b>hour</b>; adjust based on frequent serum potassium monitoring; maximum infusion rate (central line only): 40 mEq/hour with continuous ECG monitoring; some patients may require up to 400 mEq/24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-MacLaren.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-MacLaren.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3f7203a-e10c-47ac-b028-3c148b2d3e81">Parenteral nutrition</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition (off-label use): Note: </b>Parenteral nutrition ordering requires advanced knowledge of nutrient and other metabolic requirements and should only be prescribed by clinicians trained in assessment and order writing for parenteral nutrition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26078288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26078288'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Standard daily potassium requirement</i></b>: <b>IV: </b>1 to 2 mEq/kg/<b>day</b>; adjust daily dose and selection of potassium additive (eg, chloride or acetate) based on serum potassium and clinical considerations; usual maximum: 10 mEq/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ASPEN.2019','lexi-content-ref-Siparsky.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ASPEN.2019','lexi-content-ref-Siparsky.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990295"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;60 mL/minute: <b>IV, Oral:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 60 mL/minute: <b>IV, Oral:</b> No dosage adjustment necessary; use with caution and monitor potassium levels frequently to avoid overcorrection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29031359']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29031359'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Reduce initial dose by at least 50% in patients with kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929'])">Ref</a></span>); use with caution; monitor potassium levels frequently to avoid overcorrection.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral</b>: Initiate therapy at the low end of the dosing range, particularly if on other medications known to increase potassium levels; use with caution and monitor potassium levels frequently to avoid overcorrection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In patients receiving hemodialysis, the main causes of hypokalemia are low potassium dialysate, low dietary potassium intake, and malnutrition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31706619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31706619'])">Ref</a></span>). Addressing underlying causes should be simultaneously considered while assessing necessity of acute supplementation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Reduce initial dose by at least 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Use with caution; monitor potassium levels frequently to avoid overcorrection as patients receiving dialysis have little to no residual kidney function to excrete excess potassium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23946760']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23946760'])">Ref</a></span>). <b>Note:</b> Oral potassium administration is preferred in patients on dialysis unless more rapid potassium repletion is necessary (eg, severe hypokalemia associated with respiratory or cardiac instability) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23946760']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23946760'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initiate therapy at the low end of the dosing range, particularly if on other medications known to increase potassium levels; use with caution and monitor potassium levels frequently to avoid overcorrection, especially with higher doses, as patients receiving dialysis have little to no residual kidney function to excrete excess potassium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23946760']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23946760'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Dialyzable:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Address underlying causes simultaneously while assessing necessity of acute supplementation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Oral route is preferred. Consider use of the IV route if severe hypokalemia associated with respiratory or cardiac instability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23946760']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23946760'])">Ref</a></span>). Follow serum potassium levels frequently to avoid overcorrection as patients receiving dialysis have little to no residual renal function to excrete excess potassium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23946760']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23946760'])">Ref</a></span>). Reduce initial dose by at least 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initiate therapy at the low end of the dosing range, particularly if on other medications known to increase potassium levels; use with caution and monitor potassium levels frequently to avoid overcorrection, especially with higher doses, as patients receiving dialysis often have little to no residual kidney function to excrete excess potassium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23946760']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23946760'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> During CRRT, changes to potassium concentrations in the blood are best managed with changes to the dialysate or replacement solutions. Cautious potassium supplementation may be required in select circumstances (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Reduce initial dose by at least 50%; use with caution and monitor potassium levels frequently (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> There are no specific renal dose adjustments. Initiate therapy at the low end of the dosing range, particularly if on other medications known to increase potassium levels; use with caution and monitor potassium levels frequently (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> During PIRRT, changes to potassium concentrations in the blood are best managed with changes to the dialysate or replacement solutions. Cautious potassium supplementation may be required in select circumstances (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Reduce initial dose by at least 50%; use with caution and monitor potassium levels frequently (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> There are no specific renal dose adjustments. Initiate therapy at the low end of the dosing range, particularly if on other medications known to increase potassium levels; use with caution and monitor potassium levels frequently (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987597"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; use oral formulations with caution in patients with cirrhosis and start at the low end of dosage range.</p></div>
<div class="block adr drugH1Div" id="F211796"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, chest pain</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia, hyponatremia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, abdominal pain, diarrhea, flatulence, gastrointestinal hemorrhage, gastrointestinal irritation, gastrointestinal obstruction, gastrointestinal perforation, gastrointestinal ulcer, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Burning sensation at injection site, erythema at injection site, infusion-site pain, injection-site phlebitis, irritation at injection site, swelling at injection site, venous thrombosis at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Encephalopathy (hyponatremic)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p></div>
<div class="block coi drugH1Div" id="F211809"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Hypersensitivity to potassium chloride or any component of the formulation; clinically significant hyperkalemia, clinically significant hyperglycemia (dextrose-containing solutions only).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Structural, pathological, and/or pharmacologic cause for delay or arrest in passage through the GI tract (solid oral dosage forms only). <b>Note:</b> The manufacturer's labeling states concomitant use of potassium-sparing diuretics is contraindicated. While this combination should generally be avoided, in select patients under close medical supervision, combined use of potassium supplements and potassium-sparing diuretics may be considered.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Injection: Renal impairment with oliguria, anuria, or azotemia; Addison disease (untreated); ventricular fibrillation; salt-losing adrenal hyperplasia; extensive tissue breakdown as in severe burns, acute dehydration, and heat cramps; increased sensitivity to potassium administration (eg, congenital paramyotonia, adynamia episodica hereditaria); hyperadrenalism associated with adrenogenital syndrome; digitalis-induced, second- or third-degree heart block.</p></div>
<div class="block war drugH1Div" id="F211793"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vesicant/irritant (at concentrations &gt;0.1 mEq/mL); ensure proper catheter or needle position prior to and during infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperchloremia: Parenteral administration may exacerbate or cause hyperchloremia, especially in patients with or at risk of hyperchloremia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: May occur with IV or oral use. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. Use with caution or avoid use in patients with predisposing conditions for hyperkalemia (eg, chronic or severe renal impairment, extensive burns or tissue injury, heart failure, acute dehydration, systemic acidosis, adrenal insufficiency, or the administration of potassium-sparing diuretics).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity/infusion reactions: Hypersensitivity/infusion reactions, including anaphylaxis and chills, may occur with parenteral administration of potassium containing solutions. Discontinue immediately if signs/symptoms of hypersensitivity/infusion reactions develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyponatremia: Parenteral administration may cause hyponatremia; risk may be increased in children, elderly patients, postoperatively, in patients with psychogenic polydipsia, and with concurrent use of medications that may decrease sodium (eg, diuretics).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acid/base disorders: Use with caution in patients with acid/base alterations or acid/base correction; hyperosmolality or acidosis (or correction of alkalosis) is associated with hyperkalemia (shift of intracellular potassium to extracellular space); monitor serum potassium closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure, cardiac arrhythmias, atrioventricular [AV] block); patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with cirrhosis; monitor serum potassium more frequently.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; monitor serum potassium closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Oral formulations: May cause GI upset and irritation (eg, nausea, vomiting, diarrhea, abdominal pain, discomfort) and lead to GI ulceration, bleeding, perforation, and/or obstruction. Oral liquid preparations (not solid) should be used in patients with esophageal compression or delayed gastric emptying. Extended-release formulations of potassium chloride may result in a “ghost tablet” in the stool.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Parenteral administration: Do <b>NOT</b> administer undiluted or IV push; inappropriate parenteral administration may be fatal. Refer to appropriate dilution and administration rate recommendations. Use extreme caution with parenteral administration and monitor serum potassium concentrations closely. Evaluate renal function, cardiac and fluid status, and any factors contributing to altered potassium concentrations (eg, acidosis, alkalosis) prior to therapy. Pain and phlebitis may occur during parenteral infusion requiring a decrease in infusion rate or potassium concentration.</p></div>
<div class="block dosfc drugH1Div" id="F21963621"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">750 mg potassium chloride = elemental potassium 390 mg = potassium 10 mEq = potassium 10 mmol</p></div>
<div class="block foc drugH1Div" id="F211804"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Klor-Con Sprinkle: 8 mEq [DSC] [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Klor-Con Sprinkle: 10 mEq [DSC] [contains fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 8 mEq, 10 mEq</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Klor-Con: 20 mEq (1 ea, 30 ea, 100 ea) [contains fd&amp;c yellow #6 (sunset yellow); orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pokonza: 10 mEq (60 ea) [contains fd&amp;c yellow #6 (sunset yellow); orange flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mEq (1 ea, 30 ea, 50 ea, 100 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mEq (1000 mL); 40 mEq (1000 mL [DSC]); 10 mEq/100 mL (100 mL); 10 mEq/50 mL (50 mL); 20 mEq/100 mL (100 mL); 20 mEq/50 mL (50 mL); 40 mEq/100 mL (100 mL); 2 mEq/mL (5 mL, 10 mL, 20 mL, 30 mL, 250 mL [DSC]); 20 mEq/L (1000 mL); 20 mEq/L in NaCl 0.45% (1000 mL); Potassium 10 mEq/L, dextrose 5%, and sodium chloride 0.45% (1000 mL); Potassium 20 mEq/L and sodium chloride 0.45% (1000 mL); Potassium 20 mEq/L and sodium chloride 0.9% (1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.2% (500 mL [DSC], 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.225% (500 mL, 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.45% (500 mL, 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.9% (1000 mL); Potassium 30 mEq/L, dextrose 5%, and sodium chloride 0.45% (1000 mL); Potassium 40 mEq/L and sodium chloride 0.9% (1000 mL); Potassium 40 mEq/L, dextrose 5%, and sodium chloride 0.45% (1000 mL); Potassium 40 mEq/L, dextrose 5%, and sodium chloride 0.9% (1000 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mEq (1000 mL); 10 mEq/100 mL (100 mL); 10 mEq/50 mL (50 mL); 20 mEq/50 mL (50 mL); 2 mEq/mL (250 mL); 20 mEq/L (1000 mL); 0.9 mEq/L in NaCl 40% (1000 mL); 10 mEq/L in dextrose 5% (1000 mL); 20 mEq/L in NaCl 0.9% (1000 mL); Potassium 20 mEq/L and sodium chloride 0.45% (1000 mL); Potassium 20 mEq/L and sodium chloride 0.9% (1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.45% (500 mL, 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.9% (1000 mL); Potassium 40 mEq/L and sodium chloride 0.9% (1000 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mEq/15 mL (10%) (15 mL, 30 mL, 473 mL, 3800 mL [DSC]); 40 MEQ/15ML (20%) (473 mL); 40 mEq/15 mL (20%) (473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">K-Tab: 8 mEq [DSC], 10 mEq [DSC] [contains quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">K-Tab: 20 mEq</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Klor-Con: 8 mEq [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Klor-Con 10: 10 mEq [contains fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Klor-Con M10: 10 mEq</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Klor-Con M15: 15 mEq</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Klor-Con M15: 15 mEq [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Klor-Con M20: 20 mEq</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Klor-Con M20: 20 mEq [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 8 mEq, 10 mEq, 15 mEq, 20 mEq</p></div>
<div class="block geq drugH1Div" id="F211789"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F211811"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Extended Release</b> (Potassium Chloride ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mEq (per each): $0.89 - $2.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mEq (per each): $0.94 - $1.41</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Klor-Con Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq (per each): $10.74</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Pokonza Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mEq (per each): $32.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Potassium Chloride Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq (per each): $10.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (KCl (0.149%) in NaCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq/L 0.45% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq/L 0.9% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (KCl (0.298%) in NaCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mEq/L 0.9% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (KCl in Dextrose-NaCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mEq/L 5-0.45%-% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq/L 5-0.2%-% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq/L 5-0.225%-% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq/L 5-0.45%-% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq/L 5-0.9%-% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mEq/L 5-0.45%-% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mEq/L 5-0.45%-% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mEq/L 5-0.9%-% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Potassium Chloride in NaCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq/L 0.45% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq/L 0.9% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mEq/L 0.9% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Potassium Chloride Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mEq/mL (per mL): $0.24 - $1.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mEq/100 mL (per mL): $0.05 - $0.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mEq/50 mL (per mL): $0.09 - $0.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq/100 mL (per mL): $0.05 - $0.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq/50 mL (per mL): $0.09 - $0.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mEq/100 mL (per mL): $0.04 - $0.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Potassium Chloride Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 MEQ/15ML (10%) (per mL): $0.43 - $0.95</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 MEQ/15ML (20%) (per mL): $1.62 - $1.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Potassium Cl in Dextrose 5% Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mEq/L (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq/L (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (K-Tab Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq (per each): $0.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Klor-Con 10 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mEq (per each): $0.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Klor-Con M10 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mEq (per each): $0.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Klor-Con M15 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mEq (per each): $0.99</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Klor-Con M20 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq (per each): $0.63</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Klor-Con Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mEq (per each): $0.54</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Potassium Chloride Crys ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mEq (per each): $0.14 - $0.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mEq (per each): $0.16</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq (per each): $0.27 - $0.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Potassium Chloride ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mEq (per each): $0.49 - $0.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mEq (per each): $0.33 - $0.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mEq (per each): $0.47 - $0.63</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867987"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Micro-K: 8 mEq</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mEq (1000 mL); 40 mEq (1000 mL); 10 mEq/100 mL (100 mL); 20 mEq/100 mL (100 mL); 40 mEq/100 mL (50 mL, 100 mL); 2 mEq/mL (10 mL, 20 mL, 100 mL, 250 mL); Potassium 20 mEq/L and sodium chloride 0.45% (1000 mL); Potassium 20 mEq/L and sodium chloride 0.9% (1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.2% (250 mL, 500 mL, 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.225% ([DSC]); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.33% (1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.45% (500 mL, 1000 mL); Potassium 20 mEq/L, dextrose 5%, and sodium chloride 0.9% (1000 mL); Potassium 40 mEq/L and sodium chloride 0.9% (1000 mL); Potassium 40 mEq/L, dextrose 5%, and sodium chloride 0.45% (1000 mL); Potassium 40 mEq/L, dextrose 5%, and sodium chloride 0.9% (1000 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Hemodialysis: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 7.55 g (7.55 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 8 mEq</p></div>
<div class="block admp drugH1Div" id="F52613629"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: <b>Note:</b> Should be taken with meals or immediately after eating with a full glass of water or other liquid to minimize the risk of GI irritation.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule, extended release: Swallow whole, do not chew. For patients with difficulty swallowing capsules, the capsules may be opened and contents sprinkled on a spoonful of applesauce or pudding and swallowed immediately without chewing; follow with a full glass of water or juice to ensure all microcapsules are swallowed; do not add to hot foods. Any microcapsule/food mixture should be used immediately; do not save for later.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Available in two concentrations: 20 mEq per 15 mL (1.33 mEq/mL) and 40 mEq per 15 mL (2.67 mEq/mL); verify product formulation for dosage calculations. Do not administer full strength; must be diluted prior to administration. To avoid gastrointestinal irritation, the manufacturer recommends diluting potassium chloride oral solution in at least 120 mL (4 ounces) of cold water. If GI irritation occurs, increase dilution. <b>Note: </b>In postcardiac surgery pediatric patients (including neonates and infants), oral potassium chloride solution was administered at a concentration of 2.67 mEq/mL followed by an equivalent volume of sterile water (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21297518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21297518'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Powder for oral solution (Klor-Con packet): Dissolve one 20 mEq packet in 4 ounces of cold water or other beverage prior to administration. If GI irritation occurs, increase dilution.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets, sustained release and wax matrix:</p>
<p style="text-indent:-2em;margin-left:6em;">K-Tab, Kaon-Cl-10, Klor-Con: Swallow whole; do not crush, chew, or suck.</p>
<p style="text-indent:-2em;margin-left:6em;">Klor-Con M: Tablet may be broken in half and each half swallowed separately. May also dissolve whole tablet in approximately 4 ounces of water; allow approximately 2 minutes to dissolve, stir well, and drink immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: <b>Do NOT administer undiluted or by IV push; may cause fatal cardiac arrest.</b> Potassium must be diluted prior to IV infusion. In general, the dose, concentration of infusion, and rate of administration may be dependent on patient condition and specific institutional policy.</p>
<p style="text-indent:-2em;margin-left:4em;">Infusion rates (including all sources) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Greenbaum.1','lexi-content-ref-2026032','lexi-content-ref-10318297','lexi-content-ref-2310280','lexi-content-ref-23115538','lexi-content-ref-Lynch.1','lexi-content-ref-4011464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Greenbaum.1','lexi-content-ref-2026032','lexi-content-ref-10318297','lexi-content-ref-2310280','lexi-content-ref-23115538','lexi-content-ref-Lynch.1','lexi-content-ref-4011464'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Noncritical care settings: Usual range: 0.2 to 0.5 mEq/kg/hour; in adults, up to 10 to 20 mEq/hour has been reported.</p>
<p style="text-indent:-2em;margin-left:6em;">Critical care settings/situations: General recommendation to infuse at a rate ≤0.5 mEq/kg/<b>hour;</b> higher rates may be used; maximum reported rate: 1 to 2 mEq/kg/hour up to 40 mEq/hour; continuous cardiac monitoring recommended in cases of severe hypokalemia and for rates &gt;0.5 mEq/kg/hour; see institutional policy.</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant/irritant (at concentrations &gt;0.1 mEq/mL); ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do NOT flush the line); initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); remove needle/cannula; apply dry cold compresses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-24420913'])">Ref</a></span>); elevate extremity.</p></div>
<div class="block adm drugH1Div" id="F211806"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Do <b>NOT</b> administer undiluted or by IV push; may cause fatal cardiac arrest. Potassium must be diluted prior to parenteral administration. In general, the rate of administration may be dependent on patient condition and specific institution policy.</p>
<p style="text-indent:0em;margin-left:2em;">Some clinicians recommend that the maximum concentration for peripheral infusion is 10 mEq per 100 mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mount.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mount.1'])">Ref</a></span>). The maximum rate of administration for peripheral infusion is 10 mEq/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929'])">Ref</a></span>). ECG monitoring is recommended for peripheral or central infusions &gt;10 mEq/hour in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929'])">Ref</a></span>). With central line administration, higher concentrations and more rapid rates of infusion may be used; concentrations of 20 to 40 mEq per 100 mL at a maximum rate of 40 mEq/hour via central line have been safely administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2026032','lexi-content-ref-2310280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2026032','lexi-content-ref-2310280'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant/irritant (at concentrations &gt;0.1 mEq/mL); ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave needle/cannula in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate hyaluronidase antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33141794','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33141794','lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyaluronidase:</i>
<b>Intradermal or SUBQ:</b> Inject a total of 1 mL (15 units/mL) as 5 separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Oral: Oral dosage forms should be taken with meals (or immediately after eating) and a full glass of water or other liquid to minimize the risk of GI irritation. Prescribing information for the various oral preparations recommend that no more than 20 to 40 mEq should be given as single dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: MicroK: Swallow whole, do not chew. Capsules may also be opened and contents sprinkled on a spoonful of applesauce or pudding and should be swallowed immediately without chewing.</p>
<p style="text-indent:-2em;margin-left:4em;">Powder for oral solution: Klor-Con: Dissolve one packet in at least 120 mL of cold water or other beverage prior to administration. If GI irritation occurs, increase dilution.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">K-Tab, Kaon-Cl, Klor-Con: Swallow tablets whole; do not crush, chew, or suck on tablet.</p>
<p style="text-indent:-2em;margin-left:6em;">Klor-Con M: Swallow tablets whole; do not crush, chew, or suck on tablet. Tablet may also be broken in half and each half swallowed separately; the whole tablet may be dissolved in ~4 ounces of water (allow ~2 minutes to dissolve, stir well and drink immediately).</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER tablet should be swallowed whole. Do not crush, chew, or suck on tablet. Take when upright or in sitting position. A capsule formulation is available; it should be swallowed whole or alternatively opened to have contents sprinkled on a spoonful of applesauce or pudding and swallowed immediately without chewing. Klor-con M formulation may be broken in half and each half swallowed separately; the whole tablet may be dissolved in 4 ounces of water after 2 minutes—stir well and drink immediately. Effervescent tablet formulations are not advised after bariatric surgery procedures. Potassium is a known GI irritant. Minimum necessary dose and duration of potassium therapy is recommended to minimize risk of GI irritation or ulceration. Proton pump inhibitor therapy is recommended if therapy is to be continued chronically.</p></div>
<div class="block sts drugH1Div" id="F211817"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule, oral solution, tablet: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light and moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for oral solution: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Solution for injection: Store at 25°C (77°F); do not freeze; avoid excessive heat. Use only clear solutions. Potassium chloride is compatible when admixed in most common infusion solutions. Refer to institution-specific policies and procedures for stability information.</p></div>
<div class="block usep drugH1Div" id="F53568450"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment or prevention of hypokalemia (IV: FDA approved in pediatric patients [age not specified] and adults; Oral: FDA approved in all ages). <b>Note:</b> Approved ages may vary by product; consult product-specific labeling.</p></div>
<div class="block mst drugH1Div" id="F211846"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Kaon-Cl-10 may be confused with kaolin</p>
<p style="text-indent:-2em;margin-left:4em;">Kay Ciel may be confused with Kayexalate [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;">KCl may be confused with HCl</p>
<p style="text-indent:-2em;margin-left:4em;">Klor-Con may be confused with Klaron</p>
<p style="text-indent:-2em;margin-left:4em;">microK may be confused with Macrobid, Micronase</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Per The Joint Commission recommendations, concentrated electrolyte solutions should not be available in patient care areas.</p>
<p style="text-indent:-2em;margin-left:4em;">Consider special storage requirements for intravenous potassium salts; IV potassium salts have been administered IVP in error, leading to fatal outcomes.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299917"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F211798"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AMILoride: Potassium Salts may enhance the hyperkalemic effect of AMILoride.  Management: Amiloride and potassium supplements should not be used except in severe or refractory cases of hypokalemia. If coadministered, monitor serum potassium closely as rapid increases in potassium are possible.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Potassium supplements may be needed to treat/prevent hypokalemia in select patients with heart failure receiving eplerenone and high dose loop diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Potassium Salts may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: Potassium Salts may enhance the hyperkalemic effect of Spironolactone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamterene: Potassium Salts may enhance the hyperkalemic effect of Triamterene. <i> Risk X: Avoid combination</i></p></div>
<div class="block dic drugH1Div" id="F211812"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Administer with plenty of fluid to decrease stomach irritation and discomfort. Some dietary sources of potassium include leafy green vegetables (eg, spinach, cabbage), tomatoes, cucumbers, zucchini, fruits (eg, apples, oranges, and bananas), root vegetables (eg, carrots, radishes), beans, and peas.</p></div>
<div class="block pri drugH1Div" id="F5186460"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Potassium requirements are the same in pregnant and nonpregnant women. Adverse events have not been observed following use of potassium supplements in healthy women with normal pregnancies. Use caution in pregnant women with other medical conditions (eg, preeclampsia; may be more likely to develop hyperkalemia) (IOM 2004). Potassium supplementation (that does not cause maternal hyperkalemia) would not be expected to cause adverse fetal events.</p></div>
<div class="block mopp drugH1Div" id="F53568424"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Electrolytes (including serum potassium, calcium, chloride, magnesium, phosphate, calcium, sodium), glucose, acid-base balance, urine output, renal function, cardiac monitor (if intermittent IV infusion or potassium IV infusion rates &gt;0.5 mEq/kg/hour [pediatric] or &gt;10 mEq/hour [adults]) (see institutional protocols). Monitor IV infusion site. Monitor for tarry stools or other signs of GI toxicity when administering oral potassium supplement.</p></div>
<div class="block rerp drugH1Div" id="F53568313"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Potassium, serum:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Neonates &lt;7 days: 3.2 to 5.5 mmol/L (Greeley 1993; Lo 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates ≥7 to 30 days: 3.4 to 6 mmol/L (Greeley 1993; Lo 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &lt;6 months: 3.5 to 5.6 mmol/L (Greeley 1993; Lo 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months: 3.5 to 6.1 mmol/L (Greeley 1993; Lo 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;6 years: 3.3 to 4.6 mmol/L (Adeli 2015; Greeley 1993; Lo 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: 3.3 to 4.9 mmol/L (Adeli 2015; Greeley 1993; Lo 2020).</p></div>
<div class="block pha drugH1Div" id="F211792"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Potassium is the major cation of intracellular fluid and is essential for the conduction of nerve impulses in heart, brain, and skeletal muscle; contraction of cardiac, skeletal and smooth muscles; maintenance of normal renal function, acid-base balance, carbohydrate metabolism, and gastric secretion</p></div>
<div class="block phk drugH1Div" id="F211808"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Well absorbed from upper GI tract </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Enters cells via active transport from extracellular fluid </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily urine; skin and feces (small amounts); most intestinal potassium reabsorbed</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869402"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Addi k | Slow k</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cloruro de potasio norgreen | Control k | K dur | Soluc. cloruro potasio</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Kaliumchlorid fresenius kabi | Micro kalium</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Celloids pc 73 | Euro k 600 | Kali Mur | Npm potassium chloride | Perchlorcap | Schuessler Tissue Salts Glandular Tonic Kali Mur</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Electro k | KCl</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Kali-sterop | Kalium | Steropotassium</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Kalium chloratum | Kalium chloridum</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloreto de potassio | Cloreto potasio | Ionclor | Solucao de ringer com lactato de sodio</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Chlorure de Potassium "Logeais" | Kaliglutol | Kalium chloratum streuli | Kaliumchlorid Bichsel | KCl Sintetica | Kcl zyma</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Apo k</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cloruro de potasio | Kaion</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bu da xiu | Bu jia tai | Lai ding jia | Li bei jia | Potassium chloride and glucose | Slow k</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cloruro de potasio | K trol | Kaliolite | Klor con</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo k | Ardeaelytosol konc. kaliumchlorid | Kaldyum | Kalium chloratum | Kaliumchlorid | Kalnormin | Spofalyt kalium</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">1 m kaliumchlorid | Cloruro potasico braun | Kalinor-retard P | Kalium-duriles | Kaliumchlorid | KCl | Kcl zyma | Rekawan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cloruro de potasio</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cloruro de potasio | Soletrol k</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Apo k | K tab | Kaldyum | Kalii chloridum | Potmax</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Diffu k | Geo pota k | Slow k</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Potasion | Suero potasico</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Addex-kaliumklorid | Durekal | Kaleorid | Kaliduron | Kalinorm | Kalipor | Kalisol | Kalisteril | Kalitabs | Kaliumklorid braun | Kaliumklorid orifarm | Kaliumklorid sandoz | Kcl-konsentraatti</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Chlorure de potassium fresenius | Diffu k | Kalienor | Potassion</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ims potasium chloride | Intravenous potassium chloride | K contin | Micro K | Nu k</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Kalinor-retard | Kalnormin | Ksr | Slow k | Span k</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Kalij klorid</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Kaldyum | Kalium-durules | Kalium-r</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ksr</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Kay cee l</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Slow k</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Addkay | Kesol-20 | Lifepot | P-chlor | Pociel | Potasol | Potcl | Potklor | Potlyte | Potrelease</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Lento kalium | Potassio cloruro</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Apo k | Kalium</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Enkali | F zuren k | K supply | K.c.l.</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Slow k</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Daihan potassium chloride | K contin | Micro K | Pocron</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Slow k</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apo k | Kalii chloridum | Kalinor Retard P | Kalio chloridas | Kalium chlorid | Kalnormin | Spofalyt kalium</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Kalium | Kcl Retard Zyma</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Kalipoz | Rekawan | Spofalyt kalium</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Diffu k</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Cloruro potassio pisa | Corpotasin lp | K dur | Kaliolite</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Addi k | Apo k | Beacon-k | Ksr | Slow k</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Kalium</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Addex-kaliumklorid | Kaleorid | Kalinorm | Kalium | Kaliumklorid | Kaliumklorid orifarm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Blackmores Professional Celloids P.C.73 | Schuessler tissue salts kali mur</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Clorpotasium | Cloruro de potasio | Kalium</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">K chlor | K-lyte | Kaligen | Kalium | Kalium durule | Span k | Sylvite</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">K tab | K-lyte | Neo-k</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Kaldyum | Kalimat | Kalium chloratum | Katelin + SR | Potazek | Potazek max | Rekawan | Spofalyt kalium</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">K sol | K tab | Kaon Cl | Kay ciel | Klor con | Klor con M10 | Klor con M20 | Klorvess | Klotrix | Micro K | Potassium | Potassium chloride extended release</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Sandoz k8</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cloruro de potasio medicine | Perennun</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Neomaintain</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Clorura de potasiu</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Kalii chloridum | Kalii chloridum welfarm | Potassium chloride bufus</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo k</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Addex-kaliumklorid | Kaleorid | Kalipor | Kalitabs | Kalium | Kalium Nycomed | Kaliumklorid eql pharma | Kaliumklorid orifarm</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ksr</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Kalii chloridi | Kalii chloridum | Kalijev Klorid B. Braun | Lento kalium | Rekawan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Kaldyum | Kalium chloratum | Kalium chlorid | Kalnormin | Spofalyt kalium</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Addi k | Enpott | K-trolyte | Kaliject | Potassride</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Chlorure de potassium | Kalinor Retard P</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Addi k | Const-k | KCl | Pokali | Super-k</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Kalipoz prolongate | Kalium chloratum | Kalium chlorid</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cloruro de potasio | K retard</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cloruro de potasio</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Kali clorid</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Plenish-k | Slow k | Tissue salts kali mur | Ultipot</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Alkay er | Slow k</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26044506">
<a name="26044506"></a>Adeli K, Higgins V, Nieuwesteeg M, et al. Biochemical marker reference values across pediatric, adult, and geriatric ages: establishment of robust pediatric and adult reference intervals on the basis of the Canadian Health Measures Survey. <i>Clin Chem</i>. 2015;61(8):1049-1062.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/26044506/pubmed" id="26044506" target="_blank">26044506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASPEN.2019">
<a name="ASPEN.2019"></a>American Society for Parenteral and Enteral Nutrition (ASPEN). Appropriate dosing for parenteral nutrition: ASPEN recommendations. Published 2019. http://www.nutritioncare.org/PNDosing.</div>
</li>
<li>
<div class="reference">
                  American Society for Parenteral and Enteral Nutrition (ASPEN). Appropriate dosing for parenteral nutrition: ASPEN recommendations. http://www.nutritioncare.org/PNDosing. Updated November 17, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24280129">
<a name="24280129"></a>Ayers P, Adams S, Boullata J, et al; American Society for Parenteral and Enteral Nutrition. ASPEN parenteral nutrition safety consensus recommendations.<i> JPEN J Parenter Enteral Nutr.</i> 2014;38(3):296-333. doi:10.1177/0148607113511992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/24280129/pubmed" id="24280129" target="_blank">24280129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28378030">
<a name="28378030"></a>Bonilla-Félix M. Potassium regulation in the neonate. <i>Pediatr Nephrol</i>. 2017;32(11):2037-2049.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/28378030/pubmed" id="28378030" target="_blank">28378030</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23946760">
<a name="23946760"></a>Choi HY, Ha SK. Potassium balances in maintenance hemodialysis. <i>Electrolyte Blood Press</i>. 2013;11(1):9-16. doi:10.5049/EBP.2013.11.1.9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/23946760/pubmed" id="23946760" target="_blank">23946760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31706619">
<a name="31706619"></a>Clase CM, Carrero JJ, Ellison DH, et al; Conference Participants. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney Int</i>. 2020;97(1):42-61. doi:10.1016/j.kint.2019.09.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/31706619/pubmed" id="31706619" target="_blank">31706619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10979053">
<a name="10979053"></a>Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice: a contemporary review by the National Council on Potassium in Clinical Practice. <i>Arch Intern Med.</i> 2000;160(16):2429-2436. doi:10.1001/archinte.160.16.2429<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/10979053/pubmed" id="10979053" target="_blank">10979053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Corkins.1">
<a name="Corkins.1"></a>Corkins MR, Balint J, Bobo E, et al, eds. <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>. 2nd ed. Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23616673">
<a name="23616673"></a>Couture J, Létourneau A, Dubuc A, Williamson D. Evaluation of an electrolyte repletion protocol for cardiac surgery intensive care patients. <i>Can J Hosp Pharm.</i> 2013;66(2):96-103. doi:10.4212/cjhp.v66i2.1231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/23616673/pubmed" id="23616673" target="_blank">23616673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sperling.1">
<a name="Sperling.1"></a>Diabetes mellitus. In: Sperling MA, ed. <i>Pediatric Endocrinology</i>. 5th ed. Elsevier; 2020:chap. 21.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference">
                  Greeley C, Snell J, Colaco A, et al. Pediatric reference ranges for electrolytes and creatinine. <i>Clin Chem</i>. 1993;39(6):1172.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Greenbaum.1">
<a name="Greenbaum.1"></a>Greenbaum LA. Electrolyte and acid-base disorders. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020:chap. 68.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26078288">
<a name="26078288"></a>Guenter P, Boullata JI, Ayers P, et al; Parenteral Nutrition Safety Task Force, American Society for Parenteral and Enteral Nutrition (ASPEN). Standardized competencies for parenteral nutrition prescribing: the American Society for Parenteral and Enteral Nutrition model. <i>Nutr Clin Pract.</i> 2015;30(4):570-576. doi:10.1177/0884533615591167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/26078288/pubmed" id="26078288" target="_blank">26078288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gutmann.1">
<a name="Gutmann.1"></a>Gutmann L, Conwit R. Hypokalemic periodic paralysis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 31, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2026032">
<a name="2026032"></a>Hamill RJ, Robinson LM, Wexler HR, Moote C. Efficacy and safety of potassium infusion therapy in hypokalemic critically ill patients. <i>Crit Care Med</i>. 1991;19(5):694-699.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/2026032/pubmed" id="2026032" target="_blank">2026032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15977686">
<a name="15977686"></a>Hijazi M, Al-Ansari M. Protocol-driven vs. physician-driven electrolyte replacement in adult critically ill patients. <i>Ann Saudi Med</i>. 2005;25(2):105-110. doi:10.5144/0256-4947.2005.105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/15977686/pubmed" id="15977686" target="_blank">15977686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.1">
<a name="Hirsch.1"></a>Hirsch IB, Emmett M. Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  IOM (Institute of Medicine), <i>Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate</i>, Washington, DC: National Academy Press, 2004.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19564476">
<a name="19564476"></a>Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. <i>Diabetes Care.</i> 2009;32(7):1335-1343. doi:10.2337/dc09-9032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/19564476/pubmed" id="19564476" target="_blank">19564476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10318297">
<a name="10318297"></a>Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: Pediatric patients. <i>J Pharm Technol</i>. 1989;5(3):101-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/10318297/pubmed" id="10318297" target="_blank">10318297</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Klor-Con (potassium chloride) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories LLC; August 2019.</div>
</li>
<li>
<div class="reference">
                  Klor-Con extended-release tablet (potassium chloride) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories LLC; October 2018.</div>
</li>
<li>
<div class="reference">
                  Klor-Con M extended-release tablet (potassium chloride) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories LLC; October 2020.</div>
</li>
<li>
<div class="reference">
                  Klor-Con M tablet (potassium chloride) [prescribing information]. Princeton, NJ: Sandoz Inc; October 2020.</div>
</li>
<li>
<div class="reference">
                  Klor-Con Powder (potassium chloride) [prescribing information]. Maple Grove, MN: Upsher-Smith Laboratories LLC; March 2020.</div>
</li>
<li>
<div class="reference">
                  Klor-Con Sprinkle (potassium chloride) [prescribing information]. Maple Grove, MN: Upsher-Smith Labs; September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16085929">
<a name="16085929"></a>Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. <i>Am J Health Syst Pharm</i>. 2005;62(16):1663-1682.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/16085929/pubmed" id="16085929" target="_blank">16085929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2310280">
<a name="2310280"></a>Kruse JA, Carlson RW. Rapid correction of hypokalemia using concentrated intravenous potassium chloride infusions. <i>Arch Intern Med</i>. 1990;150(3):613-617.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/2310280/pubmed" id="2310280" target="_blank">2310280</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  K-Tab (potassium chloride) [prescribing information]. North Chicago, IL: AbbVie Inc; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23115538">
<a name="23115538"></a>Lafreniere JA, Hamilton DP, Carr RR. Assessing the guidelines for potassium replacement in pediatric oncology patients receiving amphotericin B. <i>J Pediatr Pharmacol Ther</i>. 2006;11(4):223-232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/23115538/pubmed" id="23115538" target="_blank">23115538</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lo SF. Reference intervals for laboratory tests and procedures. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020:chap. 748.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lynch.1">
<a name="Lynch.1"></a>Lynch R, Wood EG, Neumayr TM. Fluid and electrolyte issues in pediatric critical illness. In: Fuhrman B, Zimmerman J, eds.<i> Pediatric Critical Care</i>. 5th ed. Elsevier Health; 2017:1007-1025.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6628223">
<a name="6628223"></a>MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/6628223/pubmed" id="6628223" target="_blank">6628223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MacLaren.1">
<a name="MacLaren.1"></a>MacLaren R, Ramsay KB, Liiva MT, Connell KA, Rocker GM, Hall RI. The development and implementation of evidence-based electrolyte replacement guidelines in the intensive care unit. <i>JCPH</i>. 1999;52(6):393-398.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15568296">
<a name="15568296"></a>Mirtallo J, Canada T, Johnson D, et al. Safe practices for parenteral nutrition. <i>JPEN J Parenter Enteral Nutr</i>. 2004;28(6):S39-S70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/15568296/pubmed" id="15568296" target="_blank">15568296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21297518">
<a name="21297518"></a>Moffett BS, McDade E, Rossano JW, Dickerson HA, Nelson DP. Enteral potassium supplementation in a pediatric cardiac intensive care unit: evaluation of a practice change. <i>Pediatr Crit Care Med</i>. 2011;12(5):552-554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/21297518/pubmed" id="21297518" target="_blank">21297518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mount.1">
<a name="Mount.1"></a>Mount DB. Clinical manifestations and treatment of hypokalemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25147175">
<a name="25147175"></a>Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/25147175/pubmed" id="25147175" target="_blank">25147175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33141794">
<a name="33141794"></a>Ong J, Van Gerpen R. Recommendations for management of noncytotoxic vesicant extravasations. <i>J Infus Nurs</i>. 2020;43(6):319-343. doi:10.1097/NAN.0000000000000392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/33141794/pubmed" id="33141794" target="_blank">33141794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29031359">
<a name="29031359"></a>Palmer BF, Clegg DJ. Treatment of abnormalities of potassium homeostasis in CKD. <i>Adv Chronic Kidney Dis</i>. 2017;24(5):319-324. doi:10.1053/j.ackd.2017.06.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/29031359/pubmed" id="29031359" target="_blank">29031359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perry.1">
<a name="Perry.1"></a>Perry H. Theophylline poisoning. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 1, 2020.</div>
</li>
<li>
<div class="reference">
                  Potassium Chloride (flexible plastic container) [prescribing information]. Lincolnshire, IL: Nexus Pharmacueticals; October 2020.</div>
</li>
<li>
<div class="reference">
                  Potassium chloride extended-release capsule [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; March 2018.</div>
</li>
<li>
<div class="reference">
                  Potassium chloride extended-release capsule [prescribing information]. Parsippany, NJ: Actavis Pharma, Inc; May 2018.</div>
</li>
<li>
<div class="reference">
                  Potassium chloride extended-release tablet [prescribing information]. Piscataway, NJ: Camber Pharmaceuticals, Inc; March 2021.</div>
</li>
<li>
<div class="reference">
                  Potassium chloride for injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; June 2022.</div>
</li>
<li>
<div class="reference">
                  Potassium chloride for injection concentrate [prescribing information]. Lake Forest, IL: Hospira Inc; June 2018.</div>
</li>
<li>
<div class="reference">
                  Potassium chloride for injection concentrate [prescribing information]. Lake Forest, IL: Hospira Inc; May 2018.</div>
</li>
<li>
<div class="reference">
                  Potassium chloride in dextrose injection [prescribing information]. Lake Forest, IL: ICU Medical Inc; October 2018.</div>
</li>
<li>
<div class="reference">
                  Potassium chloride in 0.9% Sodium Chloride injection (flexible plastic container) [prescribing information]. Lake Forest, IL: ICU Medical, Inc; October 2018.</div>
</li>
<li>
<div class="reference">
                  Potassium chloride in sodium chloride injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; December 2018.</div>
</li>
<li>
<div class="reference">
                  Potassium Chloride in 5% Dextrose [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; July 2019.</div>
</li>
<li>
<div class="reference">
                  Potassium chloride injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; January 2021.</div>
</li>
<li>
<div class="reference">
                  Potassium chloride injection [product monograph]. Mississauga, Ontario, Canada: Baxter Corporation; January 2022.</div>
</li>
<li>
<div class="reference">
                  Potassium chloride oral solution [prescribing information]. Hauppauge, NY: Saptalis Pharmaceuticals LLC; March 2021.</div>
</li>
<li>
<div class="reference">
                  Potassium chloride oral solution [prescribing information]. Livonia, MI: Major Pharmaceuticals; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4011464">
<a name="4011464"></a>Schaber DE, Uden DL, Stone FM, Singh A, Katkov H, Bessinger FB. Intravenous KCl supplementation in pediatric cardiac surgical patients. <i>Pediatr Cardiol</i>. 1985;6(1):25-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/4011464/pubmed" id="4011464" target="_blank">4011464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Siparsky.1">
<a name="Siparsky.1"></a>Siparsky N. Postoperative parenteral nutrition. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 4, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19969151">
<a name="19969151"></a>Todd SR, Sucher JF, Moore LJ, Turner KL, Hall JB, Moore FA. A multidisciplinary protocol improves electrolyte replacement and its effectiveness. <i>Am J Surg</i>. 2009;198(6):911-915. doi:10.1016/j.amjsurg.2009.04.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/19969151/pubmed" id="19969151" target="_blank">19969151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29900641">
<a name="29900641"></a>Wolfsdorf JI, Glaser N, Agus M, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. <i>Pediatr Diabetes</i>. 2018;19(Suppl 27):S155-S177. doi:10.1111/pedi.12701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/29900641/pubmed" id="29900641" target="_blank">29900641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16644656">
<a name="16644656"></a>Wolfsdorf J, Glaser N, Sperling MA; American Diabetes Association. Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association. <i>Diabetes Care</i>. 2006;29(5):1150-1159. doi:10.2337/diacare.2951150<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/16644656/pubmed" id="16644656" target="_blank">16644656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21035820">
<a name="21035820"></a>Zeitler P, Haqq A, Rosenbloom A, Glaser N; Drugs and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment. <i>J Pediatr</i>. 2011;158(1):9-14. doi:10.1016/j.jpeds.2010.09.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/potassium-chloride-pediatric-drug-information/abstract-text/21035820/pubmed" id="21035820" target="_blank">21035820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zenk.1">
<a name="Zenk.1"></a>Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>
</li></ol></div><div id="topicVersionRevision">Topic 13037 Version 883.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
